Climb Bio (CLYM) Return on Equity (2021 - 2026)
Climb Bio filings provide 6 years of Return on Equity readings, the most recent being 0.0% for Q1 2026.
- Quarterly Return on Equity changed 0.0% to 0.0% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.0% through Mar 2026, changed 0.0% year-over-year, with the annual reading at 0.0% for FY2025, 0.0% changed from the prior year.
- Return on Equity hit 0.0% in Q1 2026 for Climb Bio, up from 0.0% in the prior quarter.
- Across five years, Return on Equity topped out at 0.0% in Q1 2024 and bottomed at 0.0% in Q1 2025.
- Average Return on Equity over 5 years is 0.0%, with a median of 0.0% recorded in 2022.
- Peak annual rise in Return on Equity hit 0bps in 2022, while the deepest fall reached -1bps in 2022.
- Climb Bio's Return on Equity stood at 0.0% in 2022, then rose by 2bps to 0.0% in 2023, then dropped by -5bps to 0.0% in 2024, then dropped by -3bps to 0.0% in 2025, then rose by 4bps to 0.0% in 2026.
- Per Business Quant, the three most recent readings for CLYM's Return on Equity are 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025).